{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-095029","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.354612+00:00","generated_at":"2026-05-18T07:08:11.949373+00:00","sec_items":["3.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alaunos shareholders approve 10x increase in authorized common shares, reverse split authorization","bullets":["Stockholders approved increasing authorized common shares from 5M to 50M; amendment effective July 10, 2025.","Authorized reverse stock split at ratio between 1:5 and 1:20, at Board's discretion.","Stockholders approved raising shares available under 2020 Equity Incentive Plan from 130,745 to 1,130,745.","Elected directors: Robert W. Postma, Jaime Vieser, Holger Weis; Dale Hogue resigned before meeting and was not reelected."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-095029","json":"https://secwatch.observer/filing/0000950170-25-095029.json","markdown":"https://secwatch.observer/filing/0000950170-25-095029.md","text":"https://secwatch.observer/filing/0000950170-25-095029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025095029/0000950170-25-095029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025095029/tcrt-20250703.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T07:08:11.949373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}